Major Pharmaceuticals has initiated a voluntary nationwide recall of several lots of Levothyroxine Sodium Tablets, according to the Food and Drug Administration (FDA). The federal regulator announced the recall after determining the tablets were subpotent, meaning they do not contain the full intended amount of active ingredient and may not be fully effective. Levothyroxine is a common medication used to treat hypothyroidism and other thyroid-related conditions, such as goiters.
The FDA designated the action as a Class II recall on July 17, following the initial recall start date of July 13. A Class II designation is used for products that may cause temporary or medically reversible adverse health consequences, or where the probability of serious health consequences is remote. The tablets were distributed across the United States by Major Pharmaceuticals and Cardinal Health.
The recall affects 10-count blister packs, which were sold individually or in cartons containing 100 tablets. The specific dosages involved include 25, 50, 75, 88, 112, and 150 microgram tablets. Affected lots have expiration dates ranging from July 2026 to January 2027. The FDA did not disclose the total number of tablets or lots included in the action.
The scale of the impact involves millions of potential prescriptions, as levothyroxine is consistently among the most prescribed medications in the United States. While the exact number of bottles in this specific recall was not released, the nationwide distribution through Major Pharmaceuticals and Cardinal Health means patients in all 50 states may be affected. A patient using a subpotent 100-count carton would be taking an unreliable dose for more than three months, which could result in fluctuating blood test results and necessity for additional doctor visits to recalibrate their treatment plan.
The recall may lead to immediate changes for patients when they visit their pharmacy or check their medicine cabinets. Those with the affected blister packs may need to contact their healthcare provider to obtain a replacement prescription from a different lot or manufacturer. Pharmacies are expected to remove the specific expiration dates from their inventory, which could cause temporary localized shortages of certain dosages. Patients are advised by health officials not to stop taking thyroid medication without consulting a physician, as untreated hypothyroidism can lead to long-term health complications.
What happens next: Patients and healthcare providers should monitor the FDA's Enforcement Report for updates on specific lot numbers and distribution details. Consumers who possess the recalled tablets should contact their pharmacy or Major Pharmaceuticals for instructions on returns or replacements. The FDA has not yet provided a deadline for the completion of the recall process.